OTLK Outlook Therapeutics Inc

$OTLK I have a feeling we are all going to be in for a big surprise, with a better than expected event, such as a partnership or licensing deal, sales goals exceeded, meaningful restriction or enforcement against 503B compounded bevacizumab, etc, that quickly and dramatically re-rates the stock and share price. And I was the one who believed the FDR would result in a reversal of the CRL, which almost never happens. What I mean by that is the near impossible happened already, but the events I described above are not even close to near impossible. I put my money where my mouth is Buster 

$OTLK just sold five MSFT shares and bought 5000 OTLK shares. Let's see if it will be worth it!

$OTLK I could list countless milestones already achieved and still to come, but I’ll use just one word UNDERVALUED!

$OTLK you know something big is coming, you’ve been humbled enough, now i’s the right time to boost.

$OTLK Absolutely insane! SLS has $138.3M in cash but still needs final Phase 3 REGAL results before a potential BLA. KOD has $125.9M in cash, no product revenue and hasn’t even filed its BLA for Zenkuda, planned for Q4 2026. KOD even targets the same retina market as $OTLK , while SLS operates in oncology, a completely different field. Yet both command multi-billion-dollar valuations based largely on future hopes. Meanwhile, $OTLK raised $51.1M in net proceeds from its August offering and already has an FDA-approved product, initial European sales and a US launch ahead. Yes, commercialization, reimbursement and funding remain challenges. But why is speculative pipeline potential worth billions for SLS and KOD, while OTLK’s approved product and commercial opportunity receive so little recognition? All three carry risks, but $OTLK is clearly further along the path to commercialization. This valuation gap is absolutely ridiculous, in my view 👀

$OTLK The launch cannot be that far off. My hope is we get some license deal at the same time. If this can burn through that 55 million share overhang with a good run because of those two things this would be golden. Plenty of cash and proof someone really believes in it.

$OTLK Nobody seems willing to sell! Selling pressure looks almost nonexistent. Shares appear to be in strong hands, and with such a thin float, even a little buying pressure could send us FLYING! 🚀🔥 Imagine what happens when real positive news hits!!

$OTLK The AMD drug market is estimated at roughly $10B-$12B+ globally and growing, with North America representing the largest regional share. A single product, Eylea, generated an estimated $11.15 billion global market value in 2026 according to industry market reports covering Eylea-related sales and market activity.OTLK is not trying to replace Eylea or Vabysmo completely. Its opportunity is mainly in the massive off-label bevacizumab segment: Many retina specialists already use bevacizumab because it is much cheaper. LYTENAVA™ is the first FDA-approved ophthalmic bevacizumab formulation. If physicians switch from compounded bevacizumab to FDA-approved LYTENAVA, OTLK could capture meaningful revenue without needing dominant market share. Back-of-the-Envelope OTLK Scenarios If LYTENAVA captures: 1% of a ~$10B market → roughly $100M/year opportunity 2% → roughly $200M/year 5% → roughly $500M/year

$OTLK These pirates painted the close at $0.52, but the accumulation pattern looks crystal clear to me. Strong hands are loading up while they try to shake out retail. The next few trading days should tell the story. Buy as much as you can afford! 🚀

$OTLK I have been observing today's action and I believe we are cooking or the big whales know something that we don't yet. I added additional 1000 shares to my position of already 7.500. Looking to make it 10.000! Finally volume seem to grow, and the selling pressure was almost non-existent. Level 2 data was showing that at some point buy orders for $0.01 under market were removed, because simply noone was filling them!

$OTLK This stock has been under accumulation for MONTHS. Anyone who can't see it is simply BLIND! 👀 It looks like most of the float has been absorbed by strong hands after a massive accumulation process. Selling pressure appears exhausted, and shares seem tightly held. One significant positive catalyst could trigger an EXPLOSIVE move to the upside! 🚀🔥 The longer the accumulation, the bigger the potential breakout. 💎🙌

$OTLK share price is getting higher and higher, hope accumulation is done and we’re about to get the news launch soon

$OTLK Patience, we are nearly there. Launch is around the corner and soon it will be all about sales. Dont worry about little daily drops (which mostly recover anyway by day's end) Stay bullish! Launch followed by sales numbers is key. This time next year we will be asking if we can leave $10 behind and shoot for $20.

$OTLK Plenty of room to run. No need for possible reverse split until March and then an extension to October would be highly likely. This won’t be this low for long.

$OTLK • May 19: Intraday low of $0.2150 • June 22: Intraday high of $1.88 • That is a move of roughly +775% in about 5 weeks. That was the result of the FDR win, which still carried the risk of another CRL This shows you how quickly it can move, so don’t let today’s share price bother you.

$OTLK Very important for OTLK!!!!!!! EyePoint is not only claiming that LUCIA failed to meet its target. The company is prematurely ending the LUGANO and LUCIA clinical trials for wet age-related macular degeneration (wet AMD), without completing the second year of follow-up, and cutting approximately 53% of its workforce. The restructuring is expected to generate savings of approximately $30 million annually, a one-time severance cost of about $9 million, and the reallocation of the remaining resources to the DURAVYU program for diabetic macular edema (DME). So, while management states that it will "evaluate next steps" in the field of wet AMD, its actions speak louder than words: operationally, the wet AMD program has been suspended indefinitely. For OTLK, this is far more important than the statistical details of the trial.

$OTLK So much news over the past 2–3 months about building the commercial team, a US launch planned before the end of 2026 that’s now just around the corner, and 8 years of regulatory work for the US market finally behind them. The retina market is huge, and in my view, this share price is a joke!

$OTLK it’s insane that companies like SLS and KOD have a multi billion dollar valuation without having any approved assets, while we are sitting here at a bit over a 100m

$OTLK so many retards in here spamming useless shit calm the fuck down. buy the stock or sell i dont give fuck. do your own research.

$OTLK Market is down everywhere on inflation news. Good thing with OTLK is that the movements are also big on the plus side. OTLK rises faster than it goes down and with few penny change, the percentage value appears large but remember, you only lose if you sell. Bears are banking on that but we know what we own. My 40k shares will trade 6x to 8x by this time next year.